Last reviewed: June 26, 2026

Last updated: June 26, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide dosing for weight loss follows a gradual escalation protocol, typically starting at 0.25 mg weekly and increasing by 0.25 mg increments every four weeks. Clinical trials show that most patients reach meaningful weight reduction at doses between 1.0 mg and 2.4 mg weekly, though individual response varies based on metabolic factors and genetic predisposition. PlexusDx delivers compounded semaglutide injections from licensed 503A pharmacies, allowing your healthcare provider to adjust your dose while keeping your monthly cost flat.

Understanding Semaglutide Starting Doses for Weight Management

Semaglutide injection therapy begins with a low initial dose to allow your body to adapt and minimize gastrointestinal side effects. The standard starting dose is 0.25 mg injected subcutaneously once per week, a dose designed to activate GLP-1 receptors without overwhelming your system. This conservative approach helps your appetite regulation pathways respond gradually while your healthcare provider monitors tolerability. Most patients report manageable appetite reduction and stable energy levels at this entry dose, making the first four weeks a critical baseline period.

The dose escalation schedule typically follows a four-week interval pattern, where your provider increases the dose by 0.25 mg every month unless side effects or clinical response warrant a different timeline. By week four, your dose moves to 0.5 mg weekly; by week eight, 0.75 mg; and by week twelve, 1.0 mg. This methodical approach allows your metabolic system to adapt to GLP-1 signaling while your healthcare team assesses weight loss progress, hunger changes, and any emerging tolerability concerns.

Typical Therapeutic Dosage Range and Weight Loss Outcomes

The therapeutic sweet spot for most patients falls between 1.0 mg and 2.4 mg weekly, with the 2.4 mg dose representing the maximum approved for weight management in branded semaglutide products. Clinical trial data shows that doses at 2.4 mg produce average weight loss of 15 to 18 percent of baseline body weight over 68 weeks when combined with lifestyle modification. However, meaningful weight reduction often occurs at lower doses: the 1.0 mg weekly dose produces approximately 10 to 13 percent weight loss in clinical populations, a clinically significant outcome for many patients. Your individual optimal dose depends on your body's GLP-1 receptor sensitivity, which can be influenced by genetic variants such as GLP1R rs6923761 and GIPR rs1800437.

Dose response is not linear, meaning that doubling your dose does not necessarily double your weight loss results. Many patients achieve their target weight and metabolic improvements at 1.0 to 1.5 mg weekly and choose to maintain at that level rather than escalate further. PlexusDx works with your healthcare provider to identify the dose that delivers your desired clinical outcome while maintaining tolerability. Your dose may need to go up as your metabolism adapts, but your price won't—PlexusDx charges a flat monthly rate regardless of dose level, ensuring transparent and predictable treatment costs.

Dose Adjustment Timing and How Your Body Adapts

Your body's adaptation to semaglutide influences the timing and pace of dose adjustments, with most patients requiring four to six weeks at each dose level to assess full response. During the first two weeks at a new dose, appetite suppression may feel pronounced, then often plateaus as your body establishes a new homeostatic balance. Your healthcare provider monitors this pattern through patient-reported hunger scales, weekly weight trends, and metabolic markers to determine if escalation should proceed on schedule or pause. Some patients reach their clinical goals before reaching maximum dose, while others benefit from continuing escalation to achieve their weight loss targets.

Genetic factors affecting peptide sensitivity may explain why some patients respond dramatically to lower doses while others require higher doses for similar results. The Precision Peptide Genetic Test from PlexusDx analyzes 14 metabolic pathways and 49 peptide markers, including variants in the GLP-1 receptor gene and related signaling molecules, to help your provider predict your personalized dose trajectory. This genetic insight, available as a $99 add-on after your first month of treatment, can accelerate your path to optimal dosing by reducing trial-and-error adjustment cycles.

Maintenance Dosing and Long-Term Weight Loss Stability

Once you and your healthcare provider identify your optimal maintenance dose, most patients continue at that level for sustained weight loss and weight maintenance over months and years. Maintenance doses typically range from 1.0 mg to 2.4 mg weekly, representing a stable state where appetite regulation remains consistent and weight loss has plateaued at your target. Clinical data shows that weight loss achieved during the dose escalation phase is largely preserved during maintenance, provided lifestyle habits around nutrition and movement remain consistent. Some patients require dose adjustments if metabolic adaptation occurs over extended periods, though this is less common than dose increases during the initial escalation phase.

PlexusDx compounded semaglutide injections are dispensed through licensed 503A compounding pharmacies, ensuring consistent quality and purity at your prescribed maintenance dose. Your monthly cost remains flat whether you maintain at 1.0 mg or escalate to 2.4 mg, eliminating financial barriers to dose optimization. Treatment can be managed entirely through telehealth visits with PlexusDx partner clinicians, and medications ship to all 50 states without insurance requirements. Many patients pair long-term semaglutide therapy with the Precision Peptide Genetic Test to understand their individual metabolic architecture and refine their treatment plan for maximum sustainability.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What happens if I don't tolerate the starting dose of semaglutide?

If you experience significant nausea, vomiting, or other side effects at 0.25 mg, your PlexusDx provider can extend the time at that dose, reduce meal size further, or adjust hydration and food timing before escalating. Most side effects diminish within days to weeks as your body adapts. In rare cases, semaglutide may not be the right fit, and your provider can discuss alternative GLP-1 therapies or compounded options.

How does compounded semaglutide dosing differ from brand-name Wegovy?

PlexusDx compounded semaglutide from licensed 503A pharmacies offers identical active pharmaceutical ingredients but with more flexible dose customization and significantly lower cost, starting at $149/mo. While Wegovy follows a fixed escalation schedule, compounded semaglutide can be titrated to your individual needs and genetic profile with provider oversight.

Can genetic testing predict my ideal semaglutide dose?

The Precision Peptide Genetic Test analyzes variants in GLP1R (rs6923761), GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313), among 46 other peptide markers, to map your metabolic response patterns. While genetics cannot perfectly predict your optimal dose, these insights help your PlexusDx provider anticipate whether you may be a rapid responder or require gradual escalation, reducing adjustment cycles.

Is my semaglutide injection HSA or FSA eligible?

Yes, PlexusDx compounded semaglutide injections are HSA and FSA eligible, making treatment more affordable for eligible patients. Verify with your plan administrator, but most qualifying health savings accounts cover FDA-approved active ingredients in compounded form when prescribed by a licensed provider.

What if I reach my weight loss goal before the typical maximum dose?

Many patients achieve their target weight and metabolic improvements at doses between 1.0 and 1.5 mg weekly and choose to maintain at that level. Your PlexusDx provider will work with you to establish a long-term maintenance plan that keeps you at your goal weight without unnecessary dose escalation. Your monthly price remains flat regardless of your maintenance dose.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves